Eli Lilly and Company stock slips 0.97% to EUR 1,256.70
Published on 11/04/2026 at 08:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points for investors
- Third-quarter revenue increased 39% to USD 24.4 billion, led mainly by Mounjaro and Zepbound.
- Lilly raised its 2026 revenue guidance to USD 91 billion to USD 92 billion.
- Acquisition-related research charges reduced the adjusted earnings outlook despite stronger sales expectations.
Eli Lilly and Company stock traded at EUR 1,256.70 on Lang & Schwarz at 08:07 CET on Wednesday, November 4, 2026, 0.97 percent below the Xetra close of EUR 1,269.00 on Tuesday, November 3, 2026.
Strong sales, tougher earnings mix
Lilly's third-quarter revenue increased 39 percent to USD 24.4 billion, according to the company's third-quarter results release. Mounjaro and Zepbound were the main growth drivers, keeping demand for Lilly's diabetes and obesity portfolio at the center of the investment case.
The company raised its 2026 revenue guidance to USD 91 billion to USD 92 billion. At the same time, acquisition-related research charges reduced the adjusted earnings outlook. The combination leaves investors weighing stronger operating momentum against a higher cost base from Lilly's expansion and deal activity.
Near-term attention is likely to remain on prescription volume, manufacturing capacity and the durability of demand for incretin medicines. The company is also scheduled to hold an Innovation event on December 7, according to Pharmavoice.
US equities provide the broader market backdrop for Eli Lilly and Company stock; see current S&P 500 market coverage.
More news and analyses on Eli Lilly and Company stock cover the company's outlook, pipeline and market performance.
